{
  "combination": {
    "prompt": "direct_mcode_evidence_based_concise",
    "model": "gpt-4-turbo"
  },
  "success": true,
  "cv_average_score": 1.0,
  "cv_std_score": 0.0,
  "fold_scores": [
    1.0,
    1.0,
    1.0,
    1.0,
    1.0
  ],
  "cv_folds": 3,
  "total_trials": 5,
  "total_elements": 108,
  "errors": [],
  "timestamp": "2025-09-19T09:38:05.360502",
  "metrics": {
    "precision": 1.0,
    "recall": 1.0,
    "f1_score": 1.0
  },
  "predicted_mcode": [
    {
      "element_type": "ResearchStudy",
      "code": "Not Applicable",
      "display": "Single Group Assignment",
      "system": "Not Applicable",
      "confidence_score": 1.0,
      "evidence_text": "\"interventionModel\": \"SINGLE_GROUP\""
    },
    {
      "element_type": "ResearchStudy",
      "code": "Not Applicable",
      "display": "Diagnostic",
      "system": "Not Applicable",
      "confidence_score": 1.0,
      "evidence_text": "\"primaryPurpose\": \"DIAGNOSTIC\""
    },
    {
      "element_type": "ResearchStudy",
      "code": "Not Applicable",
      "display": "No Masking",
      "system": "Not Applicable",
      "confidence_score": 1.0,
      "evidence_text": "\"masking\": \"NONE\""
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Malignant neoplasm of breast",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Conditions: Breast Cancer"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Locally advanced breast carcinoma",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "* Histologically confirmed locally advanced breast carcinoma"
    },
    {
      "element_type": "TNMStage",
      "code": "Not available",
      "display": "Stage T3 T4, N2 or N3 disease",
      "system": "http://snomed.info/sct",
      "confidence_score": 0.9,
      "evidence_text": "* Stage T3 T4, N2 or N3 disease"
    },
    {
      "element_type": "PatientDemographics",
      "code": "Not available",
      "display": "Age 18 and over",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Age: * 18 and over"
    },
    {
      "element_type": "PatientDemographics",
      "code": "Not available",
      "display": "Male or female",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Sex: * Male or female"
    },
    {
      "element_type": "PerformanceStatus",
      "code": "Not available",
      "display": "Karnofsky 80-100%",
      "system": "http://snomed.info/sct",
      "confidence_score": 0.9,
      "evidence_text": "Performance status: * Karnofsky 80-100%"
    },
    {
      "element_type": "ExclusionCriteria",
      "code": "Not available",
      "display": "No history of psychiatric illness that would preclude giving informed consent",
      "system": "http://snomed.info/sct",
      "confidence_score": 0.8,
      "evidence_text": "* No history of psychiatric illness that would preclude giving informed consent"
    },
    {
      "element_type": "ExclusionCriteria",
      "code": "Not available",
      "display": "Not pregnant",
      "system": "http://snomed.info/sct",
      "confidence_score": 0.8,
      "evidence_text": "* Not pregnant"
    },
    {
      "element_type": "ExclusionCriteria",
      "code": "Not available",
      "display": "Fertile patients must use effective contraception",
      "system": "http://snomed.info/sct",
      "confidence_score": 0.8,
      "evidence_text": "* Fertile patients must use effective contraception"
    },
    {
      "element_type": "CancerCondition",
      "code": "367651003",
      "display": "Locally advanced breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "patients with locally advanced breast cancer who will undergo chemotherapy"
    },
    {
      "element_type": "CancerTreatment",
      "code": "367336001",
      "display": "Chemotherapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "patients with locally advanced breast cancer who will undergo chemotherapy"
    },
    {
      "element_type": "CancerTreatment",
      "code": "108290001",
      "display": "Surgical resection of tumor",
      "system": "http://snomed.info/sct",
      "confidence_score": 0.9,
      "evidence_text": "the patient is evaluated for surgical resection of the tumor"
    },
    {
      "element_type": "CancerTreatment",
      "code": "108314000",
      "display": "Radiation therapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 0.9,
      "evidence_text": "the patient may be offered radiation therapy"
    },
    {
      "element_type": "DiagnosticProcedure",
      "code": "77477000",
      "display": "Positron emission tomography",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "The first group of positron emission tomography (PET) scans is performed within 2 weeks before the first dose of chemotherapy."
    },
    {
      "element_type": "Medication",
      "code": "373784005",
      "display": "Iodine I 124 iododeoxyuridine",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "There is one iodine I-124 iododeoxyuridine (IUdR) PET scan"
    },
    {
      "element_type": "Medication",
      "code": "387517004",
      "display": "Fludeoxyglucose F18",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "followed by one fludeoxyglucose (FDG) PET scan"
    },
    {
      "element_type": "StudyDesign",
      "code": "N/A",
      "display": "Clinical Trial",
      "system": "N/A",
      "confidence_score": 1.0,
      "evidence_text": "This clinical trial is studying how well PET scans work in patients with locally advanced breast cancer who will undergo chemotherapy."
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Malignant neoplasm of breast",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Patients With Locally Advanced Breast Cancer"
    },
    {
      "element_type": "StudyDesign",
      "code": "N/A",
      "display": "Clinical Trial",
      "system": "N/A",
      "confidence_score": 1.0,
      "evidence_text": "PET Scans in Patients With Locally Advanced Breast Cancer"
    },
    {
      "element_type": "ResearchStudy",
      "code": "Not Applicable",
      "display": "Randomized Parallel Treatment Study",
      "system": "Not Applicable",
      "confidence_score": 1.0,
      "evidence_text": "\"allocation\": \"RANDOMIZED\", \"interventionModel\": \"PARALLEL\", \"primaryPurpose\": \"TREATMENT\""
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Malignant neoplasm of breast",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Conditions: Breast Neoplasms"
    },
    {
      "element_type": "PatientDemographics",
      "code": "N/A",
      "display": "Female patients, age 18~40",
      "system": "N/A",
      "confidence_score": 1.0,
      "evidence_text": "Female patients, age 18~40"
    },
    {
      "element_type": "CancerCondition",
      "code": "443402002",
      "display": "Adenocarcinoma of the breast",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Unilateral, operable, histologically confirmed adenocarcinoma of the breast"
    },
    {
      "element_type": "TNMStage",
      "code": "N/A",
      "display": "Stage I-III",
      "system": "N/A",
      "confidence_score": 1.0,
      "evidence_text": "Stage I-III"
    },
    {
      "element_type": "CancerCondition",
      "code": "408643008",
      "display": "Estrogen-receptor positive status",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Histological or cytological confirmation of estrogen-receptor positive (ER+) breast cancer: the immunohistochemical cut-off for ER positive status was 1% or more staining in nuclei"
    },
    {
      "element_type": "CancerCondition",
      "code": "N/A",
      "display": "HER-2 negative",
      "system": "N/A",
      "confidence_score": 1.0,
      "evidence_text": "HER-2 negative (IHC 0,1+ or 2+ with a negative in situ hybridization test by chemotherapy"
    },
    {
      "element_type": "CancerTreatment",
      "code": "N/A",
      "display": "Primary surgery with clear margins plus axillary dissection",
      "system": "N/A",
      "confidence_score": 1.0,
      "evidence_text": "Primary surgery with clear margins plus axillary dissection"
    },
    {
      "element_type": "CancerTreatment",
      "code": "N/A",
      "display": "Able to start protocol Rx within 8 weeks of surgery",
      "system": "N/A",
      "confidence_score": 0.8,
      "evidence_text": "Able to start protocol Rx within 8 weeks of surgery"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "young breast cancer patients are characterized by aggressive clinical history"
    },
    {
      "element_type": "CancerTreatment",
      "code": "417886000",
      "display": "Paclitaxel administration",
      "system": "http://snomed.info/sct",
      "confidence_score": 0.9,
      "evidence_text": "different strategies incorporating paclitaxel to anthracycline-based regimens"
    },
    {
      "element_type": "CancerTreatment",
      "code": "3729006",
      "display": "Anthracycline administration",
      "system": "http://snomed.info/sct",
      "confidence_score": 0.9,
      "evidence_text": "anthracycline-based regimens in young breast cancer patients"
    },
    {
      "element_type": "PatientDemographics",
      "code": "30525-0",
      "display": "Age",
      "system": "http://loinc.org",
      "confidence_score": 1.0,
      "evidence_text": "Operable Breast Cancer Patients Less Than 40 Years Old"
    },
    {
      "element_type": "CancerTreatment",
      "code": "n/a",
      "display": "Adjuvant Therapy",
      "system": "n/a",
      "confidence_score": 0.9,
      "evidence_text": "Adjuvant Therapy for Operable Breast Cancer Patients"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Operable Breast Cancer Patients"
    },
    {
      "element_type": "ResearchStudy",
      "code": "Not Applicable",
      "display": "Randomized Parallel Treatment Study",
      "system": "Not Applicable",
      "confidence_score": 1.0,
      "evidence_text": "\"allocation\": \"RANDOMIZED\", \"interventionModel\": \"PARALLEL\", \"primaryPurpose\": \"TREATMENT\""
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Conditions: Breast Cancer"
    },
    {
      "element_type": "CancerCondition",
      "code": "128700001",
      "display": "Early-stage breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Early-stage Breast Cancer"
    },
    {
      "element_type": "Patient",
      "code": "N/A",
      "display": "Female",
      "system": "N/A",
      "confidence_score": 1.0,
      "evidence_text": "Females aged 18 to 70 years"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Invasive breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Patients with histologically confirmed HR+/HER2- invasive breast cancer that is sensitive to endocrine therapy"
    },
    {
      "element_type": "TNMStage",
      "code": "N/A",
      "display": "T2N1M0",
      "system": "N/A",
      "confidence_score": 1.0,
      "evidence_text": "Tumor diameter >2 cm, clinically positive axillary lymph nodes not more than 2 (T2N1M0)"
    },
    {
      "element_type": "TumorMarkerTest",
      "code": "N/A",
      "display": "Ki67 Index >=20%",
      "system": "N/A",
      "confidence_score": 1.0,
      "evidence_text": "Ki67â‰¥+20%"
    },
    {
      "element_type": "TumorMarkerTest",
      "code": "N/A",
      "display": "ER expression >50%",
      "system": "N/A",
      "confidence_score": 1.0,
      "evidence_text": "Endocrine therapy sensitivity is defined as ER expression >50% by immunohistochemistry"
    },
    {
      "element_type": "TumorMarkerTest",
      "code": "N/A",
      "display": "HER2 negative",
      "system": "N/A",
      "confidence_score": 1.0,
      "evidence_text": "HER-2 negativity is defined as HER-2 results of 0 or 1+ by immunohistochemistry, or negative by FISH"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "China is a country with a high incidence of breast cancer."
    },
    {
      "element_type": "CancerCondition",
      "code": "126906006",
      "display": "Hormone receptor positive",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "For operable hormone receptor-positive (HR+) / human epidermal growth factor receptor 2-negative (HER2-) breast cancer"
    },
    {
      "element_type": "CancerCondition",
      "code": "371973000",
      "display": "HER2-negative breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "For operable hormone receptor-positive (HR+) / human epidermal growth factor receptor 2-negative (HER2-) breast cancer"
    },
    {
      "element_type": "CancerTreatment",
      "code": "703423002",
      "display": "Neoadjuvant therapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "its efficacy in neoadjuvant settings needs further exploration."
    },
    {
      "element_type": "CancerTreatment",
      "code": "373873005",
      "display": "Endocrine therapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Endocrine therapy plays a significant role in the treatment of advanced and early-stage HR+/HER2- breast cancer"
    },
    {
      "element_type": "CancerTreatment",
      "code": "108290001",
      "display": "Chemotherapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "traditional neoadjuvant chemotherapy often fails to achieve clinical complete response (CCR) and has poor tolerability."
    },
    {
      "element_type": "CancerTreatment",
      "code": "763158003",
      "display": "CDK 4/6 inhibitor therapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "With the clinical application of CDK4/6 inhibitors, the effectiveness of neoadjuvant endocrine therapy is expected to be enhanced."
    },
    {
      "element_type": "CancerTreatment",
      "code": "430975009",
      "display": "Palbociclib",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "In PALLET study, the combination of palbociclib and letrozole significantly inhibited Ki-67 expression"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763703008",
      "display": "Abemaciclib",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "NeoMONARCH study suggests that a regimen containing abemaciclib is significantly superior to anastrozole monotherapy"
    },
    {
      "element_type": "CancerTreatment",
      "code": "703511009",
      "display": "Ribociclib",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "The NeoPAL and CORALLEEN studies indicate that neoadjuvant endocrine therapy with palbociclib or ribociclib is comparable in efficacy to neoadjuvant chemotherapy"
    },
    {
      "element_type": "CancerCondition",
      "code": "Not Available",
      "display": "HR+/HER2- Breast Cancer",
      "system": "Not Available",
      "confidence_score": 1.0,
      "evidence_text": "HR+/HER2- Breast Cancer"
    },
    {
      "element_type": "CancerTreatment",
      "code": "Not Available",
      "display": "CDK4/6 Inhibitors",
      "system": "Not Available",
      "confidence_score": 1.0,
      "evidence_text": "CDK4/6 Inhibitors in HR+/HER2- Breast Cancer"
    },
    {
      "element_type": "CancerTreatment",
      "code": "Not Available",
      "display": "Neoadjuvant Endocrine Therapy",
      "system": "Not Available",
      "confidence_score": 1.0,
      "evidence_text": "Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors"
    },
    {
      "element_type": "StudyDesign",
      "code": "Not Available",
      "display": "Randomize-controlled Study",
      "system": "Not Available",
      "confidence_score": 1.0,
      "evidence_text": "a Randomize-controlled Study"
    },
    {
      "element_type": "ResearchStudy",
      "code": "Not Applicable",
      "display": "Non-randomized Single Group Treatment Study",
      "system": "Not Applicable",
      "confidence_score": 1.0,
      "evidence_text": "\"allocation\": \"NON_RANDOMIZED\", \"interventionModel\": \"SINGLE_GROUP\", \"primaryPurpose\": \"TREATMENT\""
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Breast Neoplasms",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Conditions: Breast Neoplasms"
    },
    {
      "element_type": "CancerCondition",
      "code": "408643008",
      "display": "Carcinoma, Ductal, Breast",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Conditions: Carcinoma, Ductal, Breast"
    },
    {
      "element_type": "CancerTreatment",
      "code": "387713003",
      "display": "Mammaplasty",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Conditions: Mammaplasty"
    },
    {
      "element_type": "CancerTreatment",
      "code": "23670006",
      "display": "Mastectomy, Segmental",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Conditions: Mastectomy, Segmental"
    },
    {
      "element_type": "CancerTreatment",
      "code": "387609005",
      "display": "Lumpectomy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Conditions: Lumpectomy"
    },
    {
      "element_type": "CancerTreatment",
      "code": "180030006",
      "display": "Breast Reconstruction",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Conditions: Breast Reconstruction"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Carcinoma of breast",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Females with a history of T2N0M0 breast carcinoma"
    },
    {
      "element_type": "TNMStage",
      "code": "396087000",
      "display": "Stage II (T2 N0 M0) breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "T2N0M0 breast carcinoma"
    },
    {
      "element_type": "CancerTreatment",
      "code": "387713003",
      "display": "Surgical excision of tumor",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Surgical or endoscopic segmental mastectomy or quadrantectomy (lumpectomy)"
    },
    {
      "element_type": "CancerTreatment",
      "code": "430975009",
      "display": "Adjuvant therapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 0.9,
      "evidence_text": "patients on anti-estrogen adjuvant therapy are NOT excluded"
    },
    {
      "element_type": "PatientCharacteristicSex",
      "code": "248153007",
      "display": "Female",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Females with a history of T2N0M0 breast carcinoma"
    },
    {
      "element_type": "PatientCharacteristicAge",
      "code": "397669002",
      "display": "Adult",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "minimumAge: 18 Years"
    },
    {
      "element_type": "PatientCharacteristicAge",
      "code": "304253008",
      "display": "Elderly (65+ years)",
      "system": "http://snomed.info/sct",
      "confidence_score": 0.8,
      "evidence_text": "maximumAge: 75 Years"
    },
    {
      "element_type": "CancerTreatment",
      "code": "103328007",
      "display": "Autologous fat transplantation",
      "system": "http://snomed.info/sct",
      "confidence_score": 0.9,
      "evidence_text": "transplantation of autologous fat augmented with Adipose Derived Regenerative Cells (ADRCs)"
    },
    {
      "element_type": "CancerCondition",
      "code": "126906006",
      "display": "Breast deformity",
      "system": "http://snomed.info/sct",
      "confidence_score": 0.9,
      "evidence_text": "patients with functional and cosmetic breast deformities post segmental mastectomy or quadrantectomy (lumpectomy)"
    },
    {
      "element_type": "Procedure",
      "code": "23670006",
      "display": "Segmental mastectomy",
      "system": "http://snomed.info/sct",
      "confidence_score": 0.9,
      "evidence_text": "post segmental mastectomy or quadrantectomy (lumpectomy)"
    },
    {
      "element_type": "Procedure",
      "code": "387713003",
      "display": "Quadrantectomy",
      "system": "http://snomed.info/sct",
      "confidence_score": 0.9,
      "evidence_text": "post segmental mastectomy or quadrantectomy (lumpectomy)"
    },
    {
      "element_type": "CancerCondition",
      "code": "126906006",
      "display": "Breast deformity",
      "system": "http://snomed.info/sct",
      "confidence_score": 0.9,
      "evidence_text": "Treatment Of Patients With BrEast Deformities Post Segmental Breast ResecTion (Lumpectomy)"
    },
    {
      "element_type": "CancerTreatment",
      "code": "225358003",
      "display": "Reconstructive surgery",
      "system": "http://snomed.info/sct",
      "confidence_score": 0.9,
      "evidence_text": "Transplanted to Reconstruct Breast Deformities After Lumpectomy"
    },
    {
      "element_type": "Procedure",
      "code": "23670006",
      "display": "Lumpectomy",
      "system": "http://snomed.info/sct",
      "confidence_score": 0.9,
      "evidence_text": "Post Segmental Breast ResecTion (Lumpectomy)"
    },
    {
      "element_type": "CancerTreatment",
      "code": "108290001",
      "display": "Radiation therapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 0.8,
      "evidence_text": "With Or Without Radiation ThErapy"
    },
    {
      "element_type": "CancerCondition",
      "code": "405937009",
      "display": "HER2/Neu positive",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Conditions: HER2/Neu Positive"
    },
    {
      "element_type": "CancerCondition",
      "code": "94260004",
      "display": "Recurrent breast carcinoma",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Recurrent Breast Carcinoma"
    },
    {
      "element_type": "CancerCondition",
      "code": "254837009",
      "display": "Stage IV breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Stage IV Breast Cancer"
    },
    {
      "element_type": "CancerCondition",
      "code": "126906006",
      "display": "Stage IV breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Patients with stage IV HER2+ breast cancer treated to"
    },
    {
      "element_type": "CancerCondition",
      "code": "109838007",
      "display": "HER2 positive breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Patients with stage IV HER2+ breast cancer treated to"
    },
    {
      "element_type": "CancerTreatment",
      "code": "373873005",
      "display": "HER2-targeted monoclonal antibody therapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Patients must continue HER2-targeted monoclonal antibody therapy dosing per standard of care through the entire study period"
    },
    {
      "element_type": "CancerTreatment",
      "code": "416608001",
      "display": "Trastuzumab",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "HER2-targeted monoclonal antibody therapy is defined as either trastuzumab monotherapy"
    },
    {
      "element_type": "CancerTreatment",
      "code": "763158003",
      "display": "Pertuzumab",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "or trastuzumab and pertuzumab combination therapy administered per standard of care"
    },
    {
      "element_type": "CancerTreatment",
      "code": "26294005",
      "display": "Bisphosphonates",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Patients on bisphosphonates and/or endocrine therapy are eligible"
    },
    {
      "element_type": "CancerTreatment",
      "code": "367336001",
      "display": "Endocrine therapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Patients on bisphosphonates and/or endocrine therapy are eligible"
    },
    {
      "element_type": "CancerCondition",
      "code": "372130006",
      "display": "Stage IV breast cancer",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "patients with stage IV human epidermal growth factor receptor 2 (HER2) positive breast cancer"
    },
    {
      "element_type": "CancerTreatment",
      "code": "26294005",
      "display": "Vaccine therapy",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "Vaccines made from HER2 intracellular domain (ICD) peptide"
    },
    {
      "element_type": "CancerTreatment",
      "code": "373873005",
      "display": "Polysaccharide-K",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "polysaccharide-K may stimulate the immune system in different ways and stop tumor cells from growing"
    },
    {
      "element_type": "CancerTreatment",
      "code": "116367008",
      "display": "Trastuzumab",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "trastuzumab (or trastuzumab and pertuzumab) per standard of care"
    },
    {
      "element_type": "CancerTreatment",
      "code": "416608001",
      "display": "Pertuzumab",
      "system": "http://snomed.info/sct",
      "confidence_score": 1.0,
      "evidence_text": "trastuzumab (or trastuzumab and pertuzumab) per standard of care"
    },
    {
      "element_type": "CancerCondition",
      "code": "Not Available",
      "display": "Stage IV HER2 Positive Breast Cancer",
      "system": "Not Available",
      "confidence_score": 1.0,
      "evidence_text": "Stage IV HER2 Positive Breast Cancer"
    },
    {
      "element_type": "CancerTreatment",
      "code": "Not Available",
      "display": "HER2-Targeted Monoclonal Antibody Therapy",
      "system": "Not Available",
      "confidence_score": 1.0,
      "evidence_text": "HER2-Targeted Monoclonal Antibody Therapy"
    },
    {
      "element_type": "CancerTreatment",
      "code": "Not Available",
      "display": "Polysaccharide Krestin (PSK)",
      "system": "Not Available",
      "confidence_score": 1.0,
      "evidence_text": "Polysaccharide Krestin (PSK)"
    },
    {
      "element_type": "CancerTreatment",
      "code": "Not Available",
      "display": "HER2 ICD Peptide-Based Vaccine",
      "system": "Not Available",
      "confidence_score": 1.0,
      "evidence_text": "HER2 ICD Peptide-Based Vaccine"
    },
    {
      "element_type": "StudyDesign",
      "code": "Not Available",
      "display": "Phase I/II Randomized Study",
      "system": "Not Available",
      "confidence_score": 1.0,
      "evidence_text": "Phase I/II Randomized Study"
    },
    {
      "element_type": "PatientDemographics",
      "code": "N/A",
      "display": "Age",
      "system": "N/A",
      "confidence_score": 1.0,
      "evidence_text": "\"Age, Continuous\", \"MEDIAN\", \"FULL_RANGE\", \"years\", \"value\": \"52\", \"lowerLimit\": \"36\", \"upperLimit\": \"62\""
    },
    {
      "element_type": "PatientDemographics",
      "code": "N/A",
      "display": "Sex: Female",
      "system": "N/A",
      "confidence_score": 1.0,
      "evidence_text": "\"Sex: Female, Male\", \"COUNT_OF_PARTICIPANTS\", \"Participants\", \"Female\", \"value\": \"16\""
    },
    {
      "element_type": "PatientDemographics",
      "code": "N/A",
      "display": "Ethnicity: Not Hispanic or Latino",
      "system": "N/A",
      "confidence_score": 1.0,
      "evidence_text": "\"Ethnicity (NIH/OMB)\", \"Not Hispanic or Latino\", \"value\": \"16\""
    },
    {
      "element_type": "PatientDemographics",
      "code": "N/A",
      "display": "Race: Asian",
      "system": "N/A",
      "confidence_score": 1.0,
      "evidence_text": "\"Race (NIH/OMB)\", \"Asian\", \"value\": \"2\""
    },
    {
      "element_type": "PatientDemographics",
      "code": "N/A",
      "display": "Race: White",
      "system": "N/A",
      "confidence_score": 1.0,
      "evidence_text": "\"Race (NIH/OMB)\", \"White\", \"value\": \"14\""
    },
    {
      "element_type": "PatientDemographics",
      "code": "N/A",
      "display": "Region of Enrollment: United States",
      "system": "N/A",
      "confidence_score": 1.0,
      "evidence_text": "\"Region of Enrollment\", \"United States\", \"value\": \"16\""
    }
  ]
}